Published in:
Open Access
01-12-2016 | Review
Second- and third-generation ALK inhibitors for non-small cell lung cancer
Authors:
Jingjing Wu, John Savooji, Delong Liu
Published in:
Journal of Hematology & Oncology
|
Issue 1/2016
Login to get access
Abstract
Crizotinib as the first-generation ALK inhibitor has shown significant activity in ALK-mutated non-small cell lung cancer (NSCLC). Second- and third-generation ALK inhibitors are entering clinical applications for ALK+ NSCLC. In addition, a third-generation ALK inhibitor, lorlatinib (PF-06463922), was reported to resensitize NSCLC to crizotinib. This review provided a summary of clinical development of alectinib, ceritinib, brigatinib (AP26113), and lorlatinib.